Advertisement

Cefpodoxime

[15 July 2016]

Products Affected - Description

Cefpodoxime oral suspension, Aurobindo
50 mg/5 mL, 50 mL bottle, 1 count (NDC 65862-0140-50) - discontinued
50 mg/5 mL, 100 mL bottle, 1 count (NDC 65862-0140-01) - discontinued
100 mg/5 mL, 50 mL bottle, 1 count (NDC 65862-0141-50) - discontinued
100 mg/5 mL, 100 mL bottle, 1 count (NDC 65862-0141-01) - discontinued
 
Cefpodoxime oral suspension, Sandoz
50 mg/5 mL, 50 mL bottle, 1 count (NDC 00781-6168-52)
50 mg/5 mL, 100 mL bottle, 1 count (NDC 00781-6168-46)

Reason for the Shortage

  • Aurobindo discontinued cefpodoxime oral suspension.
  • Pfizer has discontinued Vantin.
  • Ranbaxy has an import ban on all solid medications including cefpodoxime.
  • Sandoz could not provide a reason for the shortage.

Available Products

Cefpodoxime oral tablet, Aurobindo
100 mg, 20 count (NDC 65862-0095-20)
200 mg, 20 count (NDC 65862-0096-20)
 
Cefpodoxime oral suspension, Sandoz
100 mg/5 mL, 50 mL bottle, 1 count (NDC 00781-6169-52)
100 mg/5 mL, 100 mL bottle, 1 count (NDC 00781-6169-46)
 
Cefpodoxime oral tablet, Sandoz
100 mg, 20 count (NDC 00781-5438-20)
200 mg, 20 count (NDC 00781-5439-20)
200 mg, 100 count (NDC 00781-5439-01)

Estimated Resupply Dates

  • Sandoz has cefpodoxime 50 mg/5 mL oral suspension in 50 mL and 100 mL bottles on back order and the company cannot estimate a release date.

Related Shortages

Updated

July 15, April 18, January 25, 2016; December 3, October 19, September 9, June 29 and 9, March 23, January 28, 2015; December 10, October 20, September 10, August 27 and 7, July 15, June 3, April 24, March 20 and 3, February 10, 2014; December 4, November 21 and 5, October 2, September 16, August 23, July 25, May 28 and 6, April 23 and 2, March 1, January 28, 2013; November 9, September 27, July 6, May 15, March 22, 2012; December 8, October 5, August 24, July 29, June 24, May 20, 2011, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing